CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 41 enrolled
Drug / intervention
Oral antibiotics and vaginal probiotics +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03401918
NCT03401918Phase 2Completed

Assessing the Endometrial Environment in Recurrent Pregnancy Loss and Unexplained Infertility

Stanford University·interventional·Posted Jan 17, 2018·Updated Apr 1, 2025

In Brief

A Phase 2 clinical trial evaluating Uterine ERA and microbiome testing and Oral antibiotics and vaginal probiotics for Recurrent Pregnancy Loss and Unexplained Infertility. Completed, enrolled 41 participants across 1 site.

Detailed Summary

The purpose of this study is to determine if patients with recurrent pregnancy loss or unexplained infertility have an altered uterine gene expression or uterine microbiome (micro-organism composition) during the window of embryo implantation. Furthermore we would like to assess for women with an abnormal uterine gene expression whether vaginal progesterone medication improves or alters gene expression and for women with an abnormal microbiome whether antibiotic treatment followed by probiotic treatment normalizes the microbiome.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedJan 17, 2018
Enrollment StartAug 1, 2017
Primary CompletionJul 1, 2021
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 8.5 years ago

Interventions

Uterine ERA and microbiome testingother

Uterine fluid and endometrial biopsy collection to test uterine endometrial receptivity array and microbiome.

Oral antibiotics and vaginal probioticsdrug

For subjects with abnormal microbiome results, oral antibiotics and vaginal probiotic treatment will be offered followed by a repeat uterine microbiome biopsy.